The long-term solution to the current Covid-19 pandemic is the availability of vaccines. Yet the development of a vaccine is complex, especially during a global pandemic of an unknown pathogen. Even so, many vaccine developers moved swiftly, using platform technologies to go from genetic sequence data to vaccine candidates in a few weeks. Watch the above three-part plenary session focused on the novel science of vaccines in development as well as the challenges of clinical trials, manufacturing scale-up, and global implementation. This three-part plenary discussion is facilitated by Phyllis Arthur, Vice President, Infectious Diseases and Diagnostics Policy, Biotechnology Innovation Organization (BIO).
Part 1: A Fireside chat discussion with Dr. Anthony Fauci, MD, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Dr. Anthony Fauci, MD, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Dr. Michelle McMurry-Heath, Incoming President and Chief Executive Officer, BIO
Part 2: Leveraging platforms and partnerships to develop Covid-19 vaccines in record time
As numerous vaccines move through clinical development there are important issues that need to be addressed. How will companies and partners conduct global clinical trials? What are the key scientific issues that must be addressed to vaccinate millions of people worldwide? This panel discusses the complex path to clinical trials and the impact of the evolving science on their development, as well as shares thoughts on how collaboration will bring life-saving vaccines to the world.
- Mark McClellan, MD, Director, Duke Margolis Center for Health Policy
- Gregory Glenn, MD, Chief Scientific Officer, Novavax
- Margaret Hamburg, MD, Foreign Secretary, National Academy of Medicine
- Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, United States Food and Drug Administration
- Paul Stoffels, MD, Vice Chairman of the Executive Committee, Chief Scientific Officer, Johnson & Johnson
Part 3: Global solutions for implementation: From scale-up to worldwide access
The successful development of Covid-19 vaccines is only the first part of a long-term response to the pandemic. In order to truly impact the pandemic, the global public health community will need to work together with public, private, and NGO partners to implement the delivery of billions of doses of vaccines. To help speed eventual availability, many companies and their partners are pursing global manufacturing and distribution solutions even though these vaccines are in the early stages of development. This panel discusses how the community can work together to ensure rapid and broad access to vaccines.
- Amanda Glassman, EVP of CGD, CEO of CGD Europe and Senior Fellow, Center for Global Development
- Stephane Bancel, Chief Executive Officer, Moderna
- Seth Berkeley, MD, Chief Executive Officer, The GAVI Alliance
- Richard Hatchett, MD, Chief Executive Officer, Coalition for Epidemic Preparedness Innovation (CEPI)
- John Markels, President, Global Vaccines, Merck
- Vivien Tsu, PhD, Clinical Professor, Global Health, University of Washington